完全切除BRAFV600突变黑色素瘤辅助维莫非尼治疗的健康相关生活质量
BRIM8研究评估辅助维莫非尼单药对已切除IIC-IIIC期BRAFV600突变黑色素瘤患者健康相关生活质量的影响。维莫非尼组在首周期第15和22天整体健康状况/生活质量评分平均下降17.4和17.3分,随后恢复至基线以下约10分并维持至治疗结束,治疗完成后所有评分快速回到基线。
要点
- 辅助维莫非尼治疗早期出现整体健康状况/生活质量有临床意义的下降
- 认知功能及食欲减退、疲乏、疼痛等症状评分也出现类似可逆变化
- 治疗结束后生活质量评分快速恢复至基线水平
核心结论
- 维莫非尼辅助治疗患者经历治疗或疾病相关症状及整体健康状况/生活质量有临床意义的中度恶化,但随时间缓解。
研究设计与样本
- BRIM8为3期随机对照研究(NCT01667419),纳入BRAFV600突变阳性已切除IIC-IIIC期黑色素瘤患者,随机接受维莫非尼960mg每日两次或安慰剂治疗52周(13个28天周期)。
- 患者在高完成率(>80%)下完成EORTC QLQ-C30问卷评估。
主要发现
- 维莫非尼组首周期第15天整体健康状况/生活质量评分平均下降17.4(±22.9)分,第22天下降17.3(±24.1)分。
- 随后恢复至基线以下约10分并维持至剩余治疗期。
- 除认知功能外所有功能量表及食欲减退、疲乏、疼痛症状评分呈类似趋势;认知功能各访视点较基线变化<10分。
- 计划治疗完成或提前停药后所有评分快速回到基线。
临床怎么用
- 临床应告知患者辅助维莫非尼治疗早期可能出现生活质量及症状中度恶化,但多可随时间缓解并在停药后恢复。
- 治疗期间定期评估生活质量有助于识别可逆性症状并给予支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF STUDY: The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma. METHODS: The phase 3 BRIM8 study (NCT01667419) randomised patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma to 960 mg of vemurafenib twice daily or matching placebo for 52 weeks (13 × 28-day cycles). Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3 at baseline, cycle 1 (days 1, 15 and 22), cycle 2 (days 1 and 15), day 1 of every subsequent 4-week cycle, the end-of-treatment visit and each visit during the follow-up period. RESULTS: Completion rates for the EORTC QLQ-C30 questionnaire were high (>80%). There was a mean decline in the global health status (GHS)/quality of life (QOL) score of 17.4 (±22.9) and 17.3 (±24.1) points at days 15 and 22 of cycle 1, respectively, among vemurafenib-treated patients who recovered to approximately 10 points below baseline for the remainder of the treatment period. A similar trend was observed in all functional scales except for cognitive function (<10-point change from baseline at all visits) and in the symptom scores for appetite loss, fatigue and pain. As observed for the GHS/QOL score, all scores rapidly returned to baseline after completion of planned vemurafenib treatment or treatment discontinuation. CONCLUSIONS: The schedule of HRQOL assessments allowed for an accurate and complete evaluation of the impact of acute treatment-related symptoms. Vemurafenib-treated patients experience clinically meaningful moderate worsening in some treatment- or disease-related symptoms and GHS/QOL that resolve over time.
引用
- Schadendorf D, Di Giacomo AM, Demidov L, et al. Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib. Eur J Cancer. 2019. PMID: 31704549. doi:10.1016/j.ejca.2019.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。